Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison-Reference-Cited by-同舟云学术

Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison

Published:2021-03 Issue:3 Volume:10 Page:2766-2775
ISSN:2224-5820
Container-title:Annals of Palliative Medicine
language:
Short-container-title:Ann Palliat Med

Author:

Shi Yafei,Chen Wei,Li Chunyu,Zhang Yujun,Bo Mingming,Qi Shuya,Li Guohui

Publisher

AME Publishing Company

Subject

Anesthesiology and Pain Medicine,Advanced and Specialized Nursing

Link

https://apm.amegroups.com/article/download/61894/pdf

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity;Cancer Research;2023-05-19

2. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model;Frontiers in Public Health;2023-02-24

3. Case report: A rare case of sintilimab-induced gastric stenosis and literature review;Frontiers in Oncology;2023-01-25

4. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis;Frontiers in Pharmacology;2022-09-29

5. Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases;Frontiers in Oncology;2022-07-28